EMA and Swissmedic agree on further Cooperation

Recommendation
26/27 June 2025
Barcelona, Spain
Supervision of the Pharmaceutical Supply Chain: Challenges and Opportunities
The European Medicines Agency (EMA), the Directorate General Health and Food Safety (DG SANTE) of the European Commission and the Swissmedic signed an agreement which aims at ensuring a better exchange of non-public information for the protection of the public health. It is intended to exchange information related to the safety, quality or efficacy of medicines which are either already approved or in the authorisation process in the EU or in Switzerland. A similar agreement existed in 2009/2010 at the time of the H1N1 pandemic. The new agreement has been effective since the 10 July 2015 and will be valid for five years.
To find out more please see the original note on the page of the Swissmedic.
Related GMP News
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review